60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment 60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.

Clinical Trials Market worth 81.6 billion by 2030, says Global Market Insights Inc. Selbyville, Delaware , June 13, 2022 (GLOBE NEWSWIRE) -- The clinical trials market value is expected to reach USD 81.6 billion by 2030, according to a new research report by Global Market...